FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Market Closed - Boerse Frankfurt Warrants 15:35:40 2024-06-18 EDT | ||
| 1.5 EUR | +2.74% |
|
| 1 month | -14.69% | ||
| 3 months | -72.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-18 | 1.51 | +3.42% |
| 24-06-17 | 1.46 | +5.04% |
| 24-06-14 | 1.39 | -8.55% |
| 24-06-13 | 1.52 | +2.01% |
| 24-06-12 | 1.49 | -1.32% |
Real-time Boerse Frankfurt Warrants
Last update June 18, 2024 at 03:35 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SU9AU1 |
| ISIN | DE000SU9AU18 |
| Date issued | 2024-02-14 |
| Strike | 9,550 p |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.37 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.29 € |
|---|---|
| Lowest since issue | 1.31 € |
| Spread | 0.01 € |
| Spread % | 0.65% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.5
USD
Average target price
174.4
USD
Spread / Average Target
+10.73%
- Stock Market
- Certificates
- Certificat
